€ 2.1 M
funding from IMI and EFPIA
PD-MIND’s ambition is to determine the potential effectiveness of a nicotinic receptor agonist on cognitive decline as a primary outcome measure in PD-MCI.
This could be the first systematic evidence of improvement in PD-MCI, an important and widespread condition, inasmuch as the project aims to develop a drug for the first phase 3 clinical trial for PD-MCI. Since PD affects 1% of European citizens over 65 years, this envisioned outcome is expected to have a huge socioeconomic and clinical impact.
Lygature in PD-MIND
Providing multi-disciplinary partnership management, as well as communication and dissemination expertise.
- Program management. Lygature is responsible for the overall management of the PD-MIND project such as ensuring scientific dialogue and communication across the consortium, efficient administration and timely reporting. Moreover, Lygature is responsible for information distribution within the consortium and facilitation of internal communication, a.o. by providing their proprietary “MyProjectPlaza” communication platform. This ensures transparency, efficient clarification and fine-tuning among partners. Lastly, Lygature provides impartial legal advice in various negations during the project.
- Communication and Dissemination. Lygature supports the engagement of important to the project stakeholders by establishing the communication channels through which PD-MIND will effectively interact with its key-stakeholders and support patient recruitment. Lygature will develop the project website and the communications, dissemination and exploitation plan which will contain key instruments for an effective dissemination policy.
Lygature together with
Impact of the COVID-19 pandemic on PD-MIND
The worldwide COVID-19 pandemic has inevitably impacted the PD-MIND project. Our project management team is monitoring the situation closely and is in contact with IMI, the funder of the project.
In line with measures taken by local governments, the start of the clinical trial for PD-MIND has been postponed to later this year. Postponing the start of the trial will help with reducing traffic to and from the hospitals by staff and research participants. This will, in turn, contribute to halting the spread of the virus, and ensuring the safety of our staff and participants.
PD-MIND (Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug) launches its project website
Learn more about Parkinson’s, the goal and strategy of PD-MIND, the project team and research, as well as clinical trials and patient engagement here.
PD-MIND in a nutshell:
Parkinson’s disease with mild cognitive impairment (PD-MCI) is a common condition which has important clinical consequences. There is currently no treatment available for Parkinson’s. Thus, there is an unmet clinical need to treat PD-MCI.
The PD-MIND project aims to develop a treatment for PD-MCI, by means of a clinical study involving a potential new drug thought to improve memory, learning and thought processes.
The Michael J Fox Foundation supports the PD-MIND project
A new collaborative project launched in May 2019: PD-MIND’s ambition is to determine the potential effectiveness of a nicotinic receptor agonist on cognitive decline as a primary outcome measure in PD-MCI.
The Michael J Fox Foundation for Parkinson’s Research supports the PD-MIND project by providing €182.000 for an extended MRI imaging program. This funding supports the development of useful biomarkers relevant to the PD-MIND project.